Q2 2025 · 13F-HR/A
Opaleye Management Inc.holdings as filed
Filed 2025-08-15 · accession 0001641172-25-024301
$494.1M
Reported value
41
Positions
2025-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $119.3M | 24.1% | 3,905,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $40.8M | 8.25% | 2,860,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $32.8M | 6.64% | 3,529,581 | Common | SOLE |
| 80303D305 | SNWV | SANUWAVE HEALTH INC | $32.2M | 6.52% | 980,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $30.8M | 6.24% | 2,475,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $30.7M | 6.22% | 12,600,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $30.0M | 6.07% | 475,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $19.3M | 3.90% | 535,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $14.8M | 3.00% | 1,595,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $12.4M | 2.50% | 1,680,000 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $11.9M | 2.40% | 4,110,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $9.9M | 2.00% | 186,418 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $8.6M | 1.73% | 500,000 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCES INC | $8.0M | 1.61% | 1,000,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $6.9M | 1.40% | 266,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $6.4M | 1.30% | 255,087 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $6.4M | 1.30% | 490,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $6.4M | 1.29% | 562,120 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $6.2M | 1.26% | 588,797 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $5.9M | 1.20% | 11,500,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $5.8M | 1.17% | 105,000 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS | $5.6M | 1.14% | 500,000 | Common | SOLE |
| 48576UAA4 | — | KARYOPHARM THERAPEUTICS INC | $4.6M | 0.92% | 6,000,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $4.4M | 0.88% | 3,545,000 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $4.0M | 0.82% | 903,442 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $3.9M | 0.78% | 105,000 | Common | SOLE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $3.8M | 0.76% | 2,209,998 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $2.7M | 0.56% | 666,503 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $2.7M | 0.55% | 239,319 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $2.6M | 0.53% | 210,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $2.6M | 0.52% | 855,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $2.3M | 0.47% | 775,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $2.2M | 0.45% | 1,924,300 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $2.1M | 0.43% | 390,000 | Common | SOLE |
| 05380C102 | RCEL | AVITA MEDICAL INC | $2.1M | 0.42% | 389,519 | Common | SOLE |
| 67577R102 | IRD | OPUS GENETICS INC | $1.1M | 0.23% | 1,220,000 | Common | SOLE |
| 48115J109 | DERM | JOURNEY MEDICAL CORP | $682,100 | 0.14% | 95,000 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $529,381 | 0.11% | 1,442,061 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $285,000 | 0.06% | 375,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $266,400 | 0.05% | 240,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $143,742 | 0.03% | 110,571 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.